Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
O15146
UPID:
MUSK_HUMAN
Alternative names:
Muscle-specific tyrosine-protein kinase receptor
Alternative UPACC:
O15146; Q32MJ8; Q32MJ9; Q5VZW7; Q5VZW8
Background:
Muscle, skeletal receptor tyrosine-protein kinase (MuSK) is pivotal in neuromuscular junction (NMJ) formation and maintenance, mediating postsynaptic differentiation. It activates through agrin-LRP4-MuSK signaling, leading to acetylcholine receptor (AChR) clustering, essential for muscle activation.
Therapeutic significance:
MuSK's dysfunction is linked to congenital myasthenic syndrome 9 and fetal akinesia deformation sequence 1, highlighting its potential as a therapeutic target for neuromuscular disorders.